Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I StudySuzanne Trudel, Simon J. Harrison, Alexander M. Lesokhin et al.|Blood|2021Cited by 161
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapyOliver Van Oekelen, Samir Parekh, Karthik Nath et al.|Blood|2022Cited by 103
Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patientsAdolfo Aleman, Samir Parekh, Oliver Van Oekelen et al.|Cancer Cell|2022Cited by 38